Drug intelligence / Profile preview

BSL_EP026

Development stage: Unknown
Lead developer: Biosearch Life
Administration: Oral

Overview

BSL_EP026 is a combination of plant extracts developed for the management of hyperuricemia. It contains flavonoids and rutin, which work synergistically to lower serum uric acid levels. The mechanism involves increasing urinary uric acid excretion through diuretic activity and inhibition of renal tubular reabsorption, elevating urine pH to prevent urate stone formation, and inhibiting the xanthine oxidase-mediated pathway of uric acid production from purines. It has been evaluated in clinical trials for individuals with borderline or moderately high uric acid levels.

Targets

URAT1 (Uric Acid Transporter 1)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on BSL_EP026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSL_EP026.

Explore the full profile